United Guardian UG

NASDAQ UG
$7.12 -0.02 (-0.21%)
As of: Sep 8, 2026 · 3:51 PM EDT
Key Stats
Market Cap32.71 Mn
P/E14.46
P/S2.92
Div. Yield0.07
Revenue Growth (1y) (Qtr)9.51
Add ratio to table…

About

United-Guardian, Inc. is a Delaware corporation that manufactures markets and develops specialty cosmetic personal care and sexual wellness ingredients as well as a line of healthcare products including pharmaceuticals and medical lubricants. The company traces its origins to United International Research Inc founded in 1942 by Dr Alfred R Globus and later merged with Guardian Chemical Corporation to become United-Guardian, Inc. All products except Renacidin are produced at…

Read more ↓
Sectors: Healthcare Basic Materials Sector rationale The primary sector is Healthcare because pharmaceutical products account for the largest portion of revenue (51%), including the FDA-approved drug Renacidin, and the company sells medical lubricants to medical device manufacturers. A secondary sector of Basic Materials is justified because the company also manufactures and sells specialty cosmetic and personal care ingredients (29% of sales) to other manufacturers via distributors like Brenntag and Ashland. Industries: Pharmaceuticals Pharmaceuticals Primary The company's largest revenue stream (51%) comes from pharmaceutical products, specifically Renacidin, which is an FDA-approved drug for preventing and dissolving urethral catheter calcifications. Specialty Chemicals Specialty Chemicals Secondary The company manufactures and sells specialty cosmetic and sexual wellness ingredients, which account for approximately 29% of sales, through distributors like Ashland Specialty Ingredients and Brenntag Specialties. Medical Supplies Medical Supplies Secondary The company produces medical lubricants sold directly to manufacturers of medical devices, such as catheter and surgical instrument producers, which accounts for 20% of total sales. Classified using BQ-MICS CIK: 0000101295

Geographical Breakdown of Revenue (2025)

Product and Service Breakdown of Revenue (2025)

Peer group

Peer Comparison

Companies in the Pharmaceuticals
S.No. Ticker Company matchMarket CapP/EP/STotal Debt (Qtr)
1 JNJ Johnson & Johnson primary648.48 Bn30.836.6260.73 Bn
2 ABBV AbbVie Inc. primary441.05 Bn69.836.8570.82 Bn
3 MRK Merck & Co., Inc. primary367.88 Bn116.095.5353.91 Bn
4 NVS Novartis Ag primary267.37 Bn9.283.899.59 Bn
5 PFE Pfizer Inc primary158.57 Bn36.302.4963.19 Bn
6 SNY Sanofi primary52.75 Bn11.320.9825.19 Bn
7 RVMD Revolution Medicines, Inc. primary43.75 Bn-24.74--
8 ONC BeOne Medicines Ltd. primary39.12 Bn59.656.381.07 Bn